CycloSam Therapeutics, Inc. – Trademark Portfolio
Entity Type: 03
CycloSam Therapeutics, Inc. holds 2 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 42 (Computer & Scientific) — 1 filings in this category. The portfolio also extends into Class 44 (Medical Services) across 3 Nice Classification classes. Currently, 1 trademark is registered. Notable registered marks include CYCLOSAM. The owner is based in Houston, TX.
Unit 12
2413 Ralph Street
Houston, TX 77006
Showing of trademarks Trademarks
Trademark Classifications
CycloSam Therapeutics, Inc.'s trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Scientific and technological services; industrial analysis and research services
Medical services; veterinary services; hygienic and beauty care for human beings or animals
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Frequently Asked Questions
How many trademarks does CycloSam Therapeutics, Inc. have?
CycloSam Therapeutics, Inc. has 2 U.S. trademarks filed with the USPTO. Of these, 1 registered, 1 abandoned.
What trademark classes does CycloSam Therapeutics, Inc. file in?
CycloSam Therapeutics, Inc. files trademarks across 3 Nice Classification classes. The most active classes are Class 42 (Computer & Scientific), Class 44 (Medical Services), Class 5 (Pharmaceuticals). Class 42 covers scientific and technological services; industrial analysis and research services.
What are CycloSam Therapeutics, Inc.'s most well-known trademarks?
CycloSam Therapeutics, Inc.'s registered trademark portfolio includes well-known marks such as CYCLOSAM. These are among 1 currently registered trademark in the portfolio.
What is CycloSam Therapeutics, Inc.'s trademark registration success rate?
CycloSam Therapeutics, Inc. has a 50% trademark registration rate, with 1 out of 2 resolved applications resulting in successful registration. Currently, 0 applications are pending review.